Sub Categories

Search

Newsletter

Progesterone Free In Saliva ELISA Kit Maximize

Progesterone Free In Saliva ELISA Kit

Progesterone Free Saliva ELISA Kit (DES6633) is an in-vitro quantitative protocol intended to analyse amounts of active progesterone free in saliva samples.

More details

DES6633

96 wells

£ 280.00

Progesterone Free In Saliva ELISA Kit

Specificity : Human, Salivary
Sensitivity : 5.0 pg/ml
Assay Range : 0-5000 pg/ml
Size: 96 tests

Reagents Supplied:
- Progesterone Free Microtiter Plate [96 Wells]
- Progesterone Free Calibrators [7x 1ml vials]
- Progesterone Free Controls [2x 1ml vials]
- Enzyme Conjugate [1x 7ml]
- Substrate Solution [2x 11ml]
- Stop Solution  [1x 7ml]
- Wash Solution  10x [1x 50ml]

Procedure:
This progesterone free saliva ELISA kit is a competitive solid phase enzyme-linked immunosorbent assay.
[1]. Prepare the number of microplate wells required to accommodate, controls, calibrators and patient samples.
[2]. Dispense 100μl of each control, standard and sample using new disposable tips for each of the wells.
[3]. Dispense 50μl of enzyme conjugate into each well.
[4]. Incubate for 60 minutes at room temperature, placing it on a microplate mixer. Important Note: Optimal reaction in this assay is markedly dependent on shaking of the microplate!
[5]. Discard the content of the wells and rinse the wells 4x with diluted wash solution (300μl per well). Remove as much wash solution as possible by beating the microplate on absorbent paper.
[6]. Add 200μl of substrate solution to each of the wells.
[7]. Incubate without any shaking in the dark for 30 minutes.
[8]. Stop the reaction by adding 50μl of stop solution to each of the wells.
[9]. Determine the absorbance of each well at 450 nm. It is recommended to read the wells within 15 minutes of completion. Also, it is Important that for each new run a standard curve must be included.

Intended Use:
Progesterone Free Saliva ELISA Kit is a protocol that can be used for
quantitatively determining in vitro active progesterone free in saliva.

Cross-reactivity:
The following materials have been evaluated for cross reactivity. The percentage indicates cross reactivity at 50% displacement compared to Progesterone.
- Androstenedione  [4.0%]
- 11-Desoxycorticosterone  [4.4%]
- 17α-Hydroxyprogesterone  [1.6%]
- Corticosterone  [2.1]
- Less than  [0.1%] for the following steriods when this progesterone free saliva ELISA kit is used; Androsterone, Cortisol, Cortison, Danazol, 11-Desoxycortisol, Dexamethasone, 5α-Dihydrotestosteron, Estradiol, Estriol, Estrone, Prednisolon, Prednison, Pregnenolone, Testosterone.

References
1. Journal of Clinical Endocrinology and Metabolism (1973) Vol. 36 (6): 1230-1236. Charles D., et al.
2. J. Steroid Biochem. (1987) 27 (1-3): 81-94. Ross F. Vining, Robynne A. McGinley.
3. Ann. NY Acad. Sci. (2007) 1098: 446-450. B.K. Gandara, L. Leresche, L. Mancl.
4. Fertility and Sterility (992) 58 (4): 685-690. Taru Vuorento, Ilpo Huhtaniemi
5. Amer. J. of Obstetrics & Gynecology (1983) Vol 147 (5): 557-562. Jung K. Choe, Firyal S. Khan-Dawood, M. Yusoff Dawood.
6. Fertility and Sterility (1987) Vol 47 (2): 278-283. Cedard L., et al.
7. Clinical Chemistry (1983) Vol 20 (10): 1752-1756. Ross F Vining, Robynne A McGingley, Richard G. Symons.
8. Fertility and Sterility (2001) 76 (3): 615-617. M. Gröschl, M. Rauh, P. Schmid, HG Dörr.
9. Obstetrics and Gynaecology (1988) 71 (5): 659-666. Michael R. Soules, et al.
10. Biological Psychology (2007) 74: 104-107. MM Wirth, EA Meier, BL Fredrickson, OC Schultheiss.
11. Gynecol. Endocrinol. (1992) 6: 127-134. Finn MM., et al.
12. J Steroid Biochem Molec Biol (1993) 44 (1): 69-76. Blom T., et al.
13. Fertil Steril (2006) 86: 373-379. Vitzthum VJ., et al.
14. Clin Chem. (2003) 49 (10):, 1688-1691. M Gröschl, M Rauh, HG Dörr.
15. Clinical Endocrinology (2000) 53: 615-620. O’Leary P., et al.
16. Fertility and Sterility, (1988) 50 (1): 1-15. Marguerite J.Mc.Neely, Michael R.Soules.
17. Am J Hum Biol (2006) 18: 639-653. Bond LJ., et al.
18. Fertility & Sterility (2001) 4: 847-848. Vimpeli T,. et al.
19. Journal of Endocrinology (2005) 186: 77-84. Chatterton RT., et al.
20. Clin Biochem Rev., (2006) 27: 139-146. John G. Lewis.

Special Offers